Skip to main content

Table 4 Toxicities

From: Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Toxicitya, n (%)

Grade of toxicity

p1

G1

G2

≥ G3

G0 vs G1–2 vs G3–5

G1–2 vs other

G3–5 vs other

Anemia

 IRD (n = 75)

32 (42.7%)

23 (30.7%)

9 (12.0%)

0.065

0.093

0.021

 RD (n = 129)

43 (33.3%)

36 (27.9%)

33 (25.6%)

Neutropenia

 IRD (n = 74)

22 (29.7%)

13 (17.6%)

21 (28.4%)

0.701

0.771

0.406

 RD (n = 130)

48 (36.9%)

17 (13.1%)

30 (23.1%)

Thrombocytopenia

 IRD (n = 75)

23 (30.7%)

9 (12.0%)

16 (21.3%)

0.744

0.661

0.863

 RD (n = 128)

46 (35.9%)

14 (10.9%)

29 (22.6%)

Thrombosis/

Thrombus/Embolism

 IRD (n = 64)

3 (4.7%)

–

3 (4.7%)

0.460

1.000

0.349

 RD (n = 116)

6 (5.2%)

1 (0.9%)

2 (1.7%)

Fatigue

 IRD (n = 73)

18 (24.7%)

29 (39.7%)

5 (6.8%)

0.744

0.547

0.607

 RD (n = 127)

28 (22.0%)

47 (37.0%)

12 (9.4%)

Infection

 IRD (n = 70)

9 (12.9%)

26 (37.1%)

15 (21.4%)

0.008

0.005

1.000

 RD (n = 124)

11 (8.9%)

25 (20.2%)

28 (22.5%)

Neuropathyb

 IRD (n = 75)

27 (36.0%)

12 (16.0%)

3 (4.0%)

0.011

0.144

0.049

 RD (n = 128)

42 (32.8%)

10 (7.8%)

–

Nausea, vomiting

 IRD (n = 67)

21 (31.3%)

11 (16.4%)

–

0.062

0.041

0.535

 RD (n = 119)

25 (21.2%)

13 (11.0%)

2 (1.7%)

Anorexia

 IRD (n = 67)

19 (28.4%)

3 (4.5%)

–

0.400

0.398

0.537

 RD (n = 119)

17 (14.3%)

14 (11.8%)

2 (1.7%)

Diarrhea

 IRD (n = 69)

14 (20.3%)

9 (13.0%)

1 (1.4%)

0.026

0.052

0.369

 RD (n = 118)

12 (10.2%)

11 (9.3%)

–

Constipation

 IRD (n = 65)

7 (10.8%)

1 (1.5%)

–

1.000

1.000

–

 RD (n = 115)

8 (7.0%)

6 (5.2%)

–

Exanthema/rash

 IRD (n = 4)

–

3 (75.0%)

1 (25.0%)

1.000

1.000

1.000

 RD (n = 2)

–

2 (100.0%)

–

Other (max. grade)

 IRD (n = 48)

5 (10.4%)

34 (70.8%)

9 (18.8%)

0.185

0.185

0.185

 RD (n = 60)

9 (15.0%)

32 (53.3%)

19 (31.7%)

  1. a Evaluated only for patients with terminated treatment IRD or RD. Including patients (N = 1 for IRD and N = 4 for RD) who were excluded from other analyses due to switch associated with toxicity
  2. bIncludes both previous and newly acquired neuropathy
  3. 1 p-value of Fisher’s exact test